Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 0.85 |
| ▸ | SRC | P12931 | 5/20 | 0.85 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.85 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.85 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.85 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.81 |
| ▸ | PRKCG | P05129 | 3/20 | 0.81 |
| ▸ | PRKCB | P05771 | 3/20 | 0.81 |
| ▸ | PRKCA | P17252 | 3/20 | 0.81 |
| ▸ | PRKCH | P24723 | 3/20 | 0.81 |
| ▸ | PRKCI | P41743 | 3/20 | 0.81 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.81 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.81 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.81 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.81 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145351 | 0.92 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL29375761 | 0.89 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL4301366 | 0.89 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL30368635 | 0.89 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL144578 | 0.88 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL148190 | 0.86 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL144151 | 0.85 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL8135009 | 0.85 | FGFR1 (0.83) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL8127381 | 0.85 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL8122237 | 0.84 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0790997-B1 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | claimed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| EP-0790997-B1 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | FGFR1 5/4885EGFR 2466/4885SRC 2611/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | FGFR1 5/4885EGFR 2466/4885SRC 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.